Clinical Trial Update: TP10 Use in Patients With C3 Glomerulopathy (C3G) [Phase 1]

View source ↗

Summary

A Phase 1 trial of TP10 in patients with C3 glomerulopathy (Dense Deposit Disease) has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• C3 Glomerulopathy
• Dense Deposit Disease

Drugs mentioned

• TP10

Snippet

Sponsor: University of Iowa | Conditions: Dense Deposit Disease | Phase 1 | Status: WITHDRAWN